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MODERN CONCEPTS OF THE PLATELET IN HEALTH 
AND DISEASE* 
PART I 
J. WoRTH EsTES, A.B.t 
Boston, Massachusetts 
THE platelet has long been regarded as a 
mysterious quasi-cell that appears in the 
blood in numbers that vary with certain dis-
eases, and with a multiplicity of incompletely 
described or appreciated functions and char-
acteristics. It has been the subject of a great 
deal of research, speculation and literature 
of uneven quality of hypothesis and inter-
pretation. This paper represents an attempt 
to collect the most useful knowledge about 
the platelet into a description of its normal 
and abnormal states, with a view towards 
what might be called a "unified theory of the 
platelet", with emphasis on its pathophysiol-
ogy. As will be seen, there are still many in-
completely answered questions about the 
platelet, but it is my contention that it is not 
merely a conglomerate of loosely related func-
tions, as one might suspect from the attitude 
of the literature, but rather a highly special-
i;red cell or cell particle, the various functions 
and diseases of which can be discussed as 
minor variations on a few major themes. 
Though the literature referred to in this 
paper probably is not exhaustive, it does in-
clude, in my opinion, the most significant 
advances in the study of the platelet since 
1950. No attempt has been made to discuss 
the historical development of theories about 
the platelet1. This review has been designed 
as a report on concepts of the platelet at the 
time of writing. 
STRUCTURE AND FUNCTION 
The megakaryocyte, the precursor cell of 
the platelet, has been studied in vivo and in 
vitro, and with phase contrast and standard 
microscopical technics2 • 11 • The earliest cell of 
the series is the myeloblast, which differen-
tiates in the thrombocytic line to a mega-
karyoblast. This form may undergo complete 
*Thesis written during the third year of medi-
cal school. 
tFourth-year student, Boston University School 
of Medicine. 
mitosis once and develop further, or it may 
undergo up to four mitoses in the nucleus 
only, resulting in a mature megakaryocyte 
with from two to thirty-two nuclei. There is 
probably an intermediate promegakaryocyte. 
The young megakaryocyte has a round or 
oval homogeneous, finely granular cytoplasm 
with an irregular, blurred cell membrane, and 
a slightly lobulated or round nucleus. A ma-
ture megakaryocyte is large, about 80 micra 
in diameter, with irregularly shaped baso-
philic cytoplasm containing nonrefractile 
mitochondria and coarse moderately refractile 
granules, and a thin nuclear membrane; the 
large lobulated nucleus contains heavily 
packed coarse chromatin. Fluorescein-labelled 
antibody technics demonstrate an antigen 
common to both megakaryocytes and plate-
lets10. 
Megakaryocytes are found intra- and extra-
vascularly, primarily in the bone marrow, but 
also in the spleen and lymph nodes; they are 
found intravascularly in the lungs, liver, 
kidney and other organs, rarely in the cir-
culating blood. Half of those found in the 
lungs and three-fourths of those in the spleen 
lack the usual large amount of cytoplasm. 
These cells exhibit no mobility, but they 
may be capable of phagocytosis. They turn 
over at a rate of 10 per cent per day. Only 
seventy per cent of those in the body produce 
platelets, the production of which occurs 
within 48 to 60 hours of megakaryocyte mat-
uration; in the other thirty per cent, the cells 
undergo nuclear disintegration within the 
same amount of time. It has been estimated 
that 28 to 36 per cent of the actual number 
of megakaryocytes appear in a bone marrow 
aspirate smear. 
Thrombocytopoiesis occurs either by simul-
taneous disintegration of the entire mega-
karyocyte cytoplasm, or by detachment of 
cytoplasmic pseudopod fragments. Micro-
cinematographic technics9 have shown that 
the megakaryocyte contains long thin fila-
Reprinted from THE BOSTON MEDICAL QUARTERLY, December, 1962 
ments all through Its cytoplasm; these fila-
ments have periodic enlargements of which 
platelets are formed when the filaments are 
extruded from the cell. Since the platelets 
themselves apparently contain no nuclear 
material, they are incapable of further re-
generation. 
The regulation of thrombocytopoiesis is in-
fluenced by several factors3 •12-18. One of these 
may be the number of circulating platelets 
per se, since acute stimulation may be in-
duced by thrombopheresis12, causing a release 
of megakaryocyte cytoplasm with an increased 
platelet count after three to four days, and 
chronic stimulation of the same kind causes 
an increased number of megakaryocytes. 
There is considerable evidence for humoral 
substances which are capable of stimulating 
and inhibiting platelet production. These 
substances can be fractionated from the plas-
ma15, and it is probably a balance between 
them that normally maintains platelet levels. 
There is also good evidence18 that a single 
humoral factor may be responsible for the 
proliferation of all blood cell type precursors. 
Other factors which have been reported3 to 
mobilize platelet reserves are ACTH, epi-
nephrine, serotonin and hypothermia; pyri-
dine, fats, batyl alcohol, and citrovorum fac-
tor16 will also increase thrombopoiesis. 
The morphology of the mature formed cir-
culating platelet as seen with the electron 
microscope19 is much as it appears in my ex-
perience with the phase contrast microscope, 
to the limits of resolution of the latter instru-
ment; the routine blood smear is of little use 
in differentiating the various features of the 
platelet, since the distortion produced by the 
smear is too great. The earliest stage is a 
dense, discoid form, about one to two micra 
in diameter. It contains clear hyalomeric 
cytoplasm within a double-layered membrane, 
and several granules, constituting the chro-
momere (granulomere), also within double 
membranes. Dendritic processes around the 
periphery of the cytoplasm appear next, fol-
lowed by a form with one long pseudopod-
like process. The final stage before disintegra-
tion is a ballooning of the entire platelet, with 
loss of the intracytoplasmic detail. Platelets 
probably function as intact units, not requir-
ing disintegration for normal activity; this 
will be discussed in various appropriate sec-
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tions later in this paper. 
Osmotic fragility has been shown to begin 
at 0.44 per cent sodium chloride, and is com-
plete at 0.34 per cent sodium chloride, as 
measured by the release of serotonin into the 
supernatant solution20. Magnesium and col-
loids are required for maintenance of the 
normal discoid shape 21 . 
Using various labeling technics, the life 
span of platelets has been rather uniformly 
estimated at five to eleven days, with a half-
life of two to three days22-27 • It has been sug-
gested that platelets show an aging process 
similar to that found in red blood cells, but 
most investigators postulate their random dis-
appearance from the circulation, probably 
due to a continuous intravascular process of 
coagulation. The hypocoagulable state has 
been found 25 to show a more linear curve of 
platelet disappearance resulting from less ran-
dom destruction of platelets; similarly, hyper-
coagulability has been described as a state in 
which platelet utilization is accelerated. The 
measurement of platelet life span has been 
proposed as a basis for the reclassification of 
the thrombocytopenias23, and will be used for 
that purpose in clinical sections of this report. 
The physical alterations of the platelet dur-
ing the clotting process have been subject to 
much discussion and confusion3 •28-41 . The 
definitive terminology recently proposed by 
Anstall and Hawkey42 will do much to clarify 
the situation, and is accordingly summarized 
and used in the present discussion. 
At the time of injury to a tissue, including 
its blood vessels, red blood cells release a sub-
stance, "Factor R,"34 which transforms non-
adhesive circulating platelets to platelets 
which will adhere immediately to the wound 
surface. Platelet adhesiveness is directly pro-
portional to the hematocrit, the bleeding 
time is inversely proportional to the number 
of adhesive platelets, and there is no rela-
tion between the bleeding time and the total 
number of platelets34 • An alternative sugges-
tion is that this adhesion is promoted by a 
thermolabile non-dialyzable plasma protein 
called Thrombocyte Agglutinating Factor 
(TAg) 40. This adhesiveness, or stickiness, is 
a function of the viscidity of the platelet sur-
face, is reversible, will occur in the presence 
of cooling, and requires certain divalent 
cations, primarily magnesium and manganese, 
but probably not calcium. The entire process 
is apparently unrelated to the mechanism of 
coagulation as defined by the chemical reac-
tions leading to the formation of fibrin; it is 
independent of calcium ion, antihemophilic 
factor ( AHF) , prothrombin, fibrinogen, and 
perhaps Platelet Factor 338 • 
Structural metamorphosis, traditionally re-
ferred to as viscous metamorphosis, is a series 
of progressive irreversible changes in the 
structure of the platelet. It occurs late in the 
clotting process, and is often not complete 
until after fibrin has been formed. It requires 
thrombin, magnesium, manganese, Hage-
mann Factor, and probably calcium ion. It 
is independent of plasma thromboplastin 
component (PTC, Christmas factor), plasma 
factor V (proaccelerin), plasma factor VII 
(proconvertin), fibrinogen and Platelet Fac-
tor 3, exogenously administered anticoagu-
lants, and possibly AHF and plasma thrombo-
plastin antecedent (PTA). Much more care-
ful investigation is required on these points, 
since some of these factors are reported to 
have some delaying effect. 
The effectiveness of the hemostatic plug is 
due to the structural metamorphosis of plate-
lets. The plug adheres more readily to venous 
endothelium than to that of the arterial ves-
sels, though the mechanism is not understood; 
in fact, a thrombus may be considered as an 
exaggeration of normal compensatory hemo-
static mechanisms. 
There is some as yet undefined relationship 
between platelets and capillary fragility (for 
ease of expression in a pathophysiologically 
oriented discussion, the term capillary fragil-
ity is preferable to its equally frequently used 
opposite, capillary resistance) . Increased 
fragility is always found with depressed 
platelet levels, no matter what the cause of 
the thrombocytopenia. This may be due to 
the antigenic relationship between platelets 
and endothelial cells, permitting any antibody 
which attacks platelets to attack the endo-
thelium also. This relationship may be more 
direct, since platelets have been observed to 
interact with the capillary bed cells and con-
tribute some S3504-labeled material to the 
latter3 • Adrenal cortical hormones, stimulated 
by the release of endogenous epinephrine or 
by ACTH, will reduce capillary fragility 28 ; 
the catechol amine content of platelets may 
contribute to this phenomenon. 
The vasoconstrictor serotonin, which is car-
ried by platelets and released with thrombo-
cytolysis, may also play an important role in 
hemostasis. It is discussed more fully in a sub-
sequent section. 
Structural metamorphosis is the result of 
the fusion of the chromomeres of the already 
aggregated platelets, resulting from the loss 
of protection normally afforded by the intact 
hyalomere in unshed blood, possibly an anti-
coagulant form of protection41 • The exact 
mechanism initiating breakdown of the hyalo-
mere is not known, but it may be secondary 
to the polymerization of fibrinogen on its 
surface, concomitant with the coagulation 
process. Sulfhydryl groups on the platelet 
surface are probably involved, since sulfhydryl 
inhibitors will stimulate platelet breakdown33 • 
When fibrin strands first form, they do so at a 
distance from the platelet, intact or previously 
disintegrated, but are seen to attach to the 
clumped chromomeric granules soon after, 
while the hyalomeric material remains lying 
loosely in the fibrin mesh36 • 
At this point, the other forms of platelet 
aggregation should be differentially defined 
from those described above42 . Cold-induced 
adhesion is an aggregation of platelets in-
duced by cooling and agitation, involves no 
structural change, is independent of any 
metal ions, and is reversible upon rewarming. 
Platelet clumping is due to a stickiness in-
duced in the presence of certain divalent 
cations and plasma factors upon agitation at 
37°C., and is reversible upon removal of the 
ions. Platelet agglutination is an immunologi-
cal phenomenon due to platelet antibodies 
(anti-platelet agglutinins); these will be dis-
cussed in considerable detail within the con-
text of the thrombocytopenias in Part II. 
Platelet metabolism is very active, as we 
have shown in our laboratory at the Massa-
chusetts General Hospital43, in respect to both 
anaerobic and aerobic processes, even though 
the platelet has been regarded as rather an 
incomplete cell. It has been found to contain 
most of the enzymes and coenzymes for the 
major pathways of intermediary metabolism, 
particularly those involved in glycolysis; hexo-
kinase is the rate-limiting system, as it is in 
other cell types21 •44- 46 • Fifty per cent of the 
glucose metabolized is converted to pyruvate 
and lactate; twenty per cent is lost as carbon 
dioxide and water; twenty-five per cent is 
converted to glycogen, lipids and amino acids. 
All of the human amino acids have been 
found in human platelets, with particularly 
high concentrations of the monoaminodicar-
bonic acids. Measurable amounts of acid 
phosphatase are liberated at clotting, but 
there is very little alkaline phosphatase. The 
individual platelet shows an endogenous oxy-
gen consumption equal to about two per cent 
of that of the individual white blood cell47 . 
Approximately sixty-five per cent of its 
nucleic acid is ribonucleic acid45, though the 
total amount of nucleic acid is reportedly in-
significant48. Platelets have a considerable 
amount of sulfated acid mucopolysaccha-
rides21•42, probably of a structural nature; 
they have about one-half as much sulfatase 
activity as megakaryocytes, which possess the 
greatest such enzyme activity of all blood cell 
types49 . 
About 8.5 per cent of the dry weight of 
platelets is carbohydrate, including glycogen, 
glucose and six-carbon sugar polymers47• The 
carbohydrate components are primarily in the 
form of glycoprotein48, and may be associated 
with the coagulation factors as such. There 
are also high concentrations of adenine, hy-
poxanthine and adenosine triphosphate 
(A TP) ( 21.5 micromoles A TP per 1011 
platelets) 46•48. Almost all of the energy pro-
duced by A TP is used in structural meta-
morphosis and clot retraction. There is no 
creatine phosphate or creatine phosphate 
kinase in platelets. 
The platelet lipids contain the thrombo-
plastic activity of the platelets50-55 . Most of 
this activity is due to phosphatidyl serine, and 
may be enhanced by lecithin. Phosphatidyl 
ethanolamine shows some activity only in the 
presence of the individually inactive lipids 
lecithin and sphingomyelin. Inositol phos-
phatide and cholesterol are also present in 
platelets, but have no thromboplastic effect. 
Very high lipid concentrations have an anti-
coagulant effect. The free phosphatidyl 
ethanolamine released from chylomicra post-
prandially may be partly responsible for the 
hypercoagulable state seen shortly after eat-
ing. It has been suggested53 that if the phos-
pholipid molecule is incorporated in the 
active thromboplastin of the thromboplastin 
generation test, it is in some form different 
from that in which it is found in the platelets 
originally. 
All these lipids are present in approximate-
ly the same concentrations as in red blood 
cells; there is somewhat more lecithin and 
slightly less phosphatidyl serine in platelets. 
Calcium is complexed with the platelet lipids 
in an unusual form of combination; it is non-
ionic, and is not exchangeable with radio-
active calcium55 • The binding site is prob-
ably in the cell membrane. It has been postu-
lated56 that the reactive site of the platelet is 
a membrane lipoprotein, which would be 
easily available for utilization without requir-
ing any prior reaction causing the disintegra-
tion of the platelet, and is compatible with 
the observation made above that structural 
metamorphosis and platelet disruption occur 
independently of the coagulation process. 
Serotonin, histamine and the catechol 
amines are present in significant quantities in 
platelets57-76. 
Whole blood contains 0.1-0.2 micrograms 
per cubic centimeter of serotonin ( 5-hydroxy-
tryptamine) 58, all of which is carried by the 
platelets to the extent of 0.2-0.4 micrograms 
per 109 platelets50 • The platelets have no 
serotonin attached when they leave the mega-
karyocyte; they pick it up primarily during 
their circulation through the gastrointestinal 
tract, where it is manufactured by argentaffin 
cells. A platelet retains the same molecules of 
serotonin during its entire life span. There is 
little or no serotonin in the plasma (except in 
patients with carcinoid syndrome), but all of 
that in the platelets is released into serum at 
clotting. 
Exogenous serotonin is taken up by plate-
lets both in vivo and in vitro. Slow passive 
diffusion occurs at physiologic pH, while 
active transport occurs at more acid pH (5.7-
6.5), and is limited by the passive process. 
The platelet serotonin content does not ap-
pear to be complexed within any cellular 
compartment. Most of it is actively trans-
ported into the platelet by some mechanism 
which is coupled with the energy-generating 
systems. A TP is the primary factor which 
stimulates serotonin absorption in a stoichio-
metric relation of two serotonin molecules to 
one ATP. In this regard, it is most interest-
ing to note that there is evidence of lowered 
serotonin levels associated with deficiency of 
pyridoxal, as well as diseases of folic acid defi-
ciency and megaloblastic anemias. Serotonin 
absorption is facilitated by glucose, phosphate 
and potassium, and inhibited by inhibition of 
glucose oxidation and uncouplers of oxidative 
phosphorylation (though there is some dis-
agreement about the latter). Iproniazid, 
and, to a lesser degree, isoniazid, both mono-
amine oxidase inhibitors, which reduce sero-
tonin metabolism, will induce a rise in 
platelet-bound serotonin. There is no rela-
tionship between blood serotonin levels and 
the quantity of its metabolite, 5-hydroxy-
indoleacetic acid, in the urine. 
Reserpine blocks active transport of sero-
tonin into the platelet at the cell boundary, 
and blocks whatever form of intracellular 
binding exists, though it does not affect pas-
sive diffusion. The reserpine block is effective 
even at acid pH and in the presence of potas-
sium and phosphate. Digitoxin and ouabain 
also block serotonin uptake. Platelets prein-
cubated in saline for two hours at 37°C. can-
not bind serotonin, even with the addition of 
glucose, A TP, potassium and phosphate; if 
potassium or phosphate, but not glucose or 
A TP, is added to the saline suspension, sero-
tonin uptake will proceed. 
The role of serotonin in hemostasis, in par-
ticular the platelet-dependent phases of coag-
ulation, is not known. There is no evidence 
that it takes any active part in the control of 
bleeding, and its usefulness in the hemor-
rhagic disorders is doubtful. There is evi-
dence that serotonin participates in clot re-
traction (it is known that structural meta-
morphosis and clot retraction, induced by 
thrombin, will decrease the A TP concentra-
tion - upon which serotonin depends - by 
50 per cent; cold-induced clumping does not 
alter the ATP concentration), and that it in-
hibits fibrinolysis by modifying either the 
fibrin substrate or the fibrinolytic enzyme, 
plasmin, or both. It was first studied as a 
vasoconstrictor; primarily, it increases vascu-
lar resistance and may shorten periods of 
traumatic bleeding, but these effects are 
short-lived. However, though a group of pa-
tients who were treated with reserpine had 
no serotonin in their platelets, they showed no 
defect in their coagulation properties, as 
measured by all the standard clinical labora-
tory and bedside tests. 
The release of serotonin from platelets is 
independent of the clotting process, U;ougi1 
the disruption of platelets brought about in 
clotting will bring about its release. Throm-
bin appears to release platelet serotonin; this 
effect is reduced by heparin or calcium-com-
plexing agents. An alkaline extract of kidney, 
called nephrosin, will release platelet-bound 
serotonin. Certain antigen-antibody reactions 
will also cause its release in vitro if calcium 
ion is present. 
Almost all of the histamine in the blood is 
carried by the platelets, less than 0.1 micro-
gram per 109 platelets59 • As in the case of 
serotonin, its release is independent of coagu-
lation but is induced by coagulation, throm-
bin, nephrosin, and in vitro antigen-antibody 
reactions; a factor present in fresh serum, 
most likely thromboplastin, has recently been 
shown to release rabbit platelet histamine. 
Histamine, and tryptamine, have been found 
unable to be actively transported into the 
platelet. Other factors which are known to 
release histamine from platelets are peptone 
and trypsin; but release does not occur in 
plasma in which an antigen-antibody reaction 
has previously occurred, nor with histamine 
liberators such as 48/80, or streptokinase. If 
the release of histamine from platelets does 
take part in anaphylaxis, it is probably due to 
a local vascular effect with increased capillary 
permeability, but not dependent on platelets 
per se. 
Platelets are able to bind and concentrate 
epinephrine and about one third as much 
norepinephrine. The catechol amine uptake 
is slower than that of serotonin, but is simi-
larly dependent on ATP, is enhanced by 
potassium and phosphate at low pH, and is 
blocked by reserpine. 
Clot retraction is one of the best docu-
mented functions of platelets65 , 77- 86 • It is 
proportional not only to the logarithm of the 
total number of intact viable platelets77, but 
also to the number of adhesive platelets79 • 
Further, it is directly proportional to the 
hematocrit, and to the concentration of 
fibrinogen. But, clot retraction is good in 
severe anemia and weak in polycythemia. 
Calcium (or barium, magnesium or stron-
tium) , glucose (or mannose) and thrombin, 
at appropriate pH (at least 6.0) and ionic 
strength are required for clot retraction. Ex-
cess calcium will suppress clot retraction. It 
is not inhibited by heparin. Serotonin is 
thought to be involved, especially in conjunc-
tion with an unidentified plasma protein. 
As noted before, the energy for clot retrac-
tion is supplied by ATP. The clot-retracting 
activity of platelets is in the hyalomere, and 
the coagulation-promoting activity in the 
chromomere, which probably accounts for the 
fact that freezing and thawing destroys the 
former, but has a much lesser effect on the 
latter. 
Clot retraction is not due to any physical 
change in fibrin, but to an active role of 
platelets, including structural metamorphosis. 
However, the strength and firmness of the 
clot depend not on the platelet but on the 
concentration of fibrinogen and fibrinolysin, 
though the latter has no effect on clot retrac-
tion. The force exerted by the process of clot 
retraction is insufficient to draw the vessel 
walls together to achieve hemostasis. The 
phenomenon of clot retraction seems to be 
largely responsible for restoring the patency 
of blood vessels after thrombosis80 • This 
mechanism may increase the degree of throm-
bosis as well; when the clot retracts and 
serum is expressed from it, the thrombin 
which is found in the serum may induce even 
more clotting, with enlargement of the 
thrombus. Further evidence of this possible 
mechanism is afforded by the observation 
that, in surgical patients, the platelet count is 
highest about ten days postoperatively or 
postpartum, the period associated with the 
greatest incidence of venous thrombosis - it 
will be remembered that platelets adhere 
most readily to venous endothelium, and at 
this time the outpouring of new platelets pro-
vides more adhesiveness. Hypercoagulability 
has been shown86a in ischemic heart disease 
patients, associated with, among other fac-
tors, increased thromboplastin generation and 
platelet adhesiveness, but not with increased 
numbers of platelets. 
No functional defect of clot retraction 
alone has been reported. Some diseases of the 
lungs, kidneys, liver and intestines are re-
ported to cause deficient clot retraction, but 
this probably is due to increased fibrinogen 
levels in relation to other plasma proteins, 
though abnormalities in serotonin uptake or 
release may be responsible. The majority of 
deficiencies of clot retraction are due to con-
ditions involving thrombocytopenia. 
The coagulation factors associated with 
platelets present a confusing array of data 
and speculation; an extremely lucid recem 
report by Seegers87 has been followed closely 
in the present discussion, and supplemented 
by the work of others88 • 92 • 
The following are generally accepted as 
activities of platelets which contribute to the 
coagulation process: 
Platelet Factor 1 - Plasma factor V (pro-
accelerin) 
Platelet Factor 2 - Fibrinoplastic facto~ 
Platelet Factor 3 - Prothrombin activator 
(thromboplastic activity) 
Platelet Factor 4 - Antiheparin factor 
Platelet Factor 5 - Clottable factor (fibrino-
gen) 
Platelet Factor 6 - Antifibrinolysin 
Platelet Factor 7 - Cothromboplastin (plasma 
factor VII) 
Platelet Cofactor I - AHF 
Platelet Cofactor II - exact nature undeter-
mined 
Autoprothrombin I - Plasma factor VII 
(proconvertin) 
Autoprothrombin II - PTC 
Serotonin (function unconfirmed) 
Clot retraction 
Capillary fragility (mechanism undetermined) 
Free phospholipids (contribute to thrombo-
plastic activity) 
Calcium 
Most of these factors appear to be adsorbed 
and concentrated from the plasma by plate-
lets, the adsorbing surface of the platelet 
thereby becoming the link between platelet 
aggregation at the site of injury and small 
vessel hemostasis, via the process of coagula-
tion. Thrombin, which is generated on the 
platelet surface, initiates structural meta-
morphosis; this is followed by release of the 
coagulation factors carried by the platelets 
and subsequent clotting. At the same time a 
substance known as "S-protein" clots under 
the influence of thrombin and A TP ( fibrino-
gen, which is similar, does not require A TP 
for its coagulation), and imparts firmness to 
the platelet clumps, probably by an action on 
the platelet cell membrane. "S-protein" is 
similar in contractile properties to actinomy-
cin, and traps fibrinogen in its interstices88 • 
Platelet Factor 1 represents about 6 per 
cent90 (another report88 gives a figure of 37 
per cent) of the total plasma concentration 
of plasma factor V, strongly bound to the 
platelet. Platelet Factor 2 is the ability of 
platelets to accelerate the clotting of fibrino-
gen in the presence of thrombin. 
Platelet Factor 3 is lipoprotein material 
which is not adsorbed but rather found in 
the granules of the chromomere. Its function 
is as a prothrombin activator, but it does not 
seem to be a true thromboplastin, even 
though it may be measured in the thrombo-
plastin generation test. The substance pro-
duces a prothrombin derivative which takes 
part in prothrombin activation, and itself uses 
another prothrombin derivative in the con-
version of prothrombin. 
Platelet Factor 4, which is known to be 
present in the hyalomere, antagonizes the 
action of heparin, and has rarely been found 
to be deficient in patients. Platelet Factor 5 
is probably fibrinogen, which has been dis-
cussed above. Platelet Factor 6 represents a 
large proportion of the plasma antifibrinoly-
sin activity, loosely bound to the platelet sur-
face. Platelet Factor 7 is plasma factor VII 
(proconvertin) adsorbed to the extent of 
about 2.1 per cent. 
Platelet Cofactor I is very tightly bound 
AHF, adsorbed from plasma. Platelet Cofac-
tor II is a derivative of Autoprothrombin II 
which is adsorbed PTC. Autoprothrombin I 
is adsorbed plasma factor VII; its differen-
tiation from Platelet Factor 7 is unknown. 
The other factors listed above have been 
discussed previously. Additional endogenous 
factors known to be adsorbed on platelets are 
Stuart Factor (plasma factor X), certain 
glycolytic enzymes, blood group antigens, cer-
tain phospholipids in uremic states, and some 
atypical proteins found in the dysproteine-
mias. Adsorbable exogenous factors include 
some bacteria and viruses, dextran, and India 
ink. Fibrinolysin and antithrombin are not 
adsorbed by platelets, though the latter may 
be an intracellular component. 
It is readily seen that many of the activi-
ties heretofore ascribed to platelets are in 
reality those of the plasma clotting factors, 
and not entitled to specific unique association 
with the platelet. Figure 1, modified from 
Seegers87, presents the current concept of the 
role of the platelet in the conversion of pro-
thrombin to thrombin, the major function of 
the platelet in coagulation, giving it the ap-
pearance of possessing thromboplastic activ-
ity. This involves the recognition of a di-
versity of similar but nonidentical prothrom-
bin derivatives as intermediates; it will be 
noted that Platelet Factor 3 is the most im-
portant factor derived from platelets, and is 
involved in all three pathways of prothrom-
bin conversion. 
~PROTHROMBIN~ 
Calcium I \ Calcium Plas~a factor V Plasma fadJr V 
1 Calcium Plasma factor V I 
Thromboplastin Plasma factor v Thrombin """ Platelet Factor 3 I Platelet Facto• 3 ~ .1 
Autoprothrombin I~ Autoprothromb.n II 
(Plasma facto• VII) 7 
Calcium 
I 
Plasma factor V 
I 
Platelet Factor 3 
I 
Platelet Colacto• I (AHF) 
I 
THROMBIN 
Platelet Cofactor II 
Figure 1 - Role of the Platelet in the Con-
version of Prothrombin to Thrombin. 
It is difficult for this writer to understand 
the origins or biological necessity for such an 
overlapping multiplicity of prothrombin con-
version pathways. Future researches may 
well show that the basic mechanism is much 
less complicated, though the present scheme 
is by far the simplest and most rational to 
date. 
Blood group antigens appear in platelets as 
well as in red blood cells93 •9\ but they are in 
general of considerable less antigenicity than 
those of the red blood cells. Blood group 
antigens known to be found on platelets in-
clude the A1A2BO system, C and D of the 
Rh system, K, and Tl. Those known not to 
be present include P, Lea, Leb, Lub or MN 
systems, though platelets do possess, in com-
mon with red blood cells, an antigen which is 
related to and associated with the MN sys-
tem. 
Platelets also possess, or may possess, sev-
eral antigens which are unrelated to the 
blood group antigens. One of these, known 
as Zw, is inherited as a Mendelian dominant 
and is present in 98 per cent of the Dutch 
population95 ; it has not yet been reported 
elsewhere. "Cold" and "warm" platelet ag-
glutinins have been described, but they are of 
no known clinical significance. Non-aggluti-
nating platelet antibodies have been de-
scribed, and may be responsible for decreased 
platelet survival in a few patients; they are 
identifiable with an antiglobulin consumption 
test. 
With this last exception, all of the fore-
going platelet immunological phenomena 
play an extremely rare role in disease, if at 
all. The great and important group of plate-
let antibodies which do cause platelet dys-
crasias will be discussed later in the course of 
this review. 
(To be concluded) 
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MODERN CONCEPTS OF THE PLATELET IN HEALTH AND DISEASE* 
PART II 
J. WoRTH EsTEs, A.B.t 
CLINICAL PATHOLOGY 
L ABORA TORY diagnosis and study of 
platelet dyscrasias is not difficult. Though 
new methods of determining the platelet 
count are published with alarming frequency, 
the procedure of choice at this time is that of 
Brecher et al./6 •97 which involves the enu-
meration of platelets in blood diluted with 1 
per cent ammonium oxalate under the 
phase-contrast microscope. This method, 
with an error of 10-12 per cent in my experi-
ence, as well as of others, 97 shows the normal 
platelet count to be in the range of 150,000-
450,000 per cubic millimeter. The values so 
obtained are higher than those found with 
the older indirect count, based on the number 
of red blood cells on the Wright-stained 
smear; the discrepancy is due to the lack of 
random distribution of the red blood cells on 
the smear, since most of these cells concen-
trate at the periphery rather than the center 
of the cover slip. 98 Gross estimation of the 
number of platelets on smear is not a useful 
clinical tool. 
Other quantitative and qualitative methods 
of study of platelets are discussed and out-
lined in several recent volumes/7 •99 •100 and 
will not be detailed here. The in vitro meth-
ods for studying platelet function in our labo-
ratory have recently been published/3 and 
various modifications of the standard technics 
are published, with most of the clinical papers 
referred to in this review. 
One new method, which, though it re-
quires special apparatus, seems to be useful 
in the assessment of the thrombocytopenias, is 
the use of chromium51-labeled platelets in 
measuring platelet life-span.23 This technic 
permits a reclassification of the platelet defi-
ciencies on the basis of decreased production 
or increased destruction, but is most useful in 
describing the course of the diseases and 
evaluating treatment. 
*Thesis written during the third year of medical 
school. 
tFourth-year student, Boston University School 
of Medicine. 
Diseases of platelets have been the subject 
of much discussion and many schemes of 
classification over the past ten years. We are 
only now sorting them all out and studying 
their pathophysiology with a systematic ap-
proach. The outline to be followed here is 
perhaps oversimplified, but it should serve to 
tie together some of the widely scattered frag-
ments of the literature. We will not be con-
cerned with those diseases which, although 
they show purpura as a major manifestation, 
are not diseases of the platelet itself, or which 
do not affect the platelet, such as Henoch-
Schonlein purpura. 
THROMBOCYTOPENIAS 
The thrombocytopenias, or quantitative 
defects of platelets, may be considered most 
conveniently as due either to production defi-
cits or to increased peripheral destruction, or 
to combinations of these two mechanisms. 
The traditional separation into congenital 
and acquired thrombocytopenias does not 
emphasize the pathogenetic aspects to be of 
use clinically. It is of interest that in a recent 
study of 3,342 patients referred to one clinic 
for evaluation of their bleeding diatheses, 
thrombocytopenia was the most frequent 
coagulation defect found. 101 
Thrombocytopenia due to a primary pro-
duction deficit has been attributed to many 
causes. These diseases are essentially amega-
karyocytic; the bone marrow is hypoplastic, 
and the platelets show a normal life-span, 23 
unless previous isoimmunization has occurred 
due to platelet or whole-blood transfusions. 
There are many well-studied exogenous 
causes of bone-marrow hypoplasia. 102•103 
Those which regularly depress thrombocyto-
poiesis, in sufficient dosage, include whole-
body irradiation, the oncolytic drugs and 
benzol. The latter two agents manifest their 
effects largely as aplastic anemia and are 
well described in various texts. 
The effect of irradiation on platelets has 
been well studied by several investigators 
from different points of view. Purpura was 
Reprinted from THE BOSTON MEDICAL QUARTERLY, March, 1963 
found to be one of the best clinical indica-
tions of severity of exposure to the gamma 
rays and neutrons of the 20-kiloton atom-
ic bombs dropped in Japan in 1945.104 
The platelet count remained stable for three 
to four days after the explosions, and there-
after dropped rapidly to 0 in the second 
week, as the circulating platelets were de-
pleted and not replaced by the bone mar-
row, the primary site of radiation damage. 
The platelet count remained extremely low 
for two to four weeks, during which time 
various hemorrhagic states appeared, char-
acterized by increased capillary fragility, 
clotting time and bleeding time. Patients 
exposed to about 400 roentgens or less began 
to show improvement after two to five 
weeks; those exposed to higher doses failed 
to respond to any therapy. The same clini-
cal pattern was found in victims of two 
major postwar nuclear accidents/ 05 - 107 al-
though bone-marrow transfusion was effec-
tive in 4 patients who received estimated 
doses of 600 to 1000 rem. At the same time, 
increased levels of plasma factors V and VII 
were found, due not to a direct effect of the 
irradiation but secondary to the thrombo-
cytopenia. 
Irradiation of horse platelets in vitro has 
been shown to depress certain enzyme sys-
tems, resulting in decreased oxygen con-
sumption by the platelets.108 Disintegrated 
platelets are capable of correcting the coag-
ulation deficit but not the bleeding of irradi-
ated dogs; intact platelets are required to do 
both.109 The total hemostatic defect pro-
duced by whole-body irradiation has been 
postulated to be caused by loss of the follow-
ing platelet functions; 110 ability to form 
hemostatic plugs, vasoconstrictor substance, 
interaction with AHF or other plasma fac-
tors, acceleration of prothrombin conversion, 
and clot retraction. 
There are many agents which produce 
amegakaryocytic thrombocytopenia alone or 
as one manifestation of acquired aplastic 
anemia, occasionally: several antibiotics and 
antimicrobials (chloramphenicol, sulfona-
mides, streptomycin, the tetracyclines; arseni-
cals; para-aminosalicylic acid) ; the hydan-
toins; some of the antithyroid compounds; 
phenylbutazone; several minerals (arsenic, 
gold, bismuth, silver, mercury, lead); certain 
dyes and polishes (especially the aniline 
dyes), insecticides, organic solvents and 
various nitrophenyl compounds.102 To track 
down the exact cause of the patient's dis-
ease, expert search must be made for all 
of these agents, and others, in his history. 
Endogenous causes of platelet production 
deficits are more difficult to delineate. 
Thrombocytopenic purpura is a frequent 
first clinical manifestation of "congenital" 
aplastic anemia, or may present by itself. 
Defects apparent at birth include Fanconi's 
syndrome/ 11 in which thrombocytopenia is 
associated with anemia, cutaneous pigmen-
tation, microcephaly, mental retardation, re· 
tarded growth, testicular hypoplasia, and 
other congenital abnormalities. Other, prob-
ably related, congenital amegakaryocytic 
thrombocytopenias have been reported in 
association with other varieties of anatomical 
abnormalities,112 especially absent radii. A 
maturation disorder of megakaryocytes, asso-
ciated with panmyelopathy and erythroblas-
tosis, has been reported on rare occasions, 
Hegglin's syndrome. 113 •114 The platelets 
found in this disease show abortive dendritic 
forms, increased platelet volume, and defec-
tive structural metamorphosis. The throm-
bocytopenia of DiGuglielmo's syndrome115•116 
is probably due to megakaryocytic deficiency. 
A bizarre amegakaryocytic thrombocyto-
penia occasionally occurs in heat stroke.4 •117 
At body temperatures over 106° F., the 
megakaryocytes show damage and disap-
pearance of the nuclei before cytoplasmic dis-
solution into platelets occurs (though fibrin-
olysis has been implicated as the direct 
cause of the thrombocytopenia more re-
cently) ys 
Onyalai119 •1 " 0 is a form of thrombocyto-
penic purpura, characterized by distinctive 
hemorrhagic bullae on the mucous mem-
branes of the mouth and nose, occasionally 
progressing to exsanguination due to hemor-
rhage of the urinary tract, gastrointestinal 
tract and uterus. The disease is found pre-
dominantly among the Bantus, and usually 
runs a self-limiting course, although it may 
require repeated blood transfusions. Though 
megakaryocytes appear normal on smear, 
the disease appears to be one of platelet pro-
duction, since there is no evidence of plate-
let malfunction, only of thrombocytopenia. 
The specific cure for the disease is lemon 
juice or vitamin C, but it is not yet known 
whether the basic lesion involves increased 
renal ascorbic acid excretion, or perhaps an 
unknown toxic factor. Onyalai may be re-
lated to the bleeding defect seen in the more 
important vitamin C-deficiency disease, 
scurvy. A defect in Platelet Factor 3 has 
been postulated in scurvy,'21 but a more re-
cent investigation122 presents evidence for 
occasional thrombocytopenia, and suggests 
a possible connection between vitamin C 
and the folic acid system in hematopoiesis, 
with an imbalance of this relation in some 
cases of scurvy. In this connection, it may 
be noted that thrombocytopenia is infre-
quently associated with pernicious anemia, 
and bone-marrow aspiration reveals few 
megakaryocytes and rare thrombocytopoie-
sis; the condition is reversed with liver-ex-
tract therapy. 114•123 The platelets that are 
formed are increased in volume and show 
decreased dendrite activity.l14·124 
One physiological cause of depressed 
platelet levels is menstruation. 125 During the 
fourteen days prior to the period of a nor-
mal woman, the platelet count slowly de-
creases, and returns to normal rapidly after 
the onset of menses. It is not known whether 
this is due to changes in the hormones, the 
bone marrow or the reticuloendothelial sys-
tem, but the change should be considered in 
evaluating the platelet count in women of 
the childbearing age group. 
Thrombocytopenia due to predominant 
peripheral destruction includes the most 
puzzling of all platelet dyscrasias. There is 
still considerable controversy over some of 
these diseases, and the literature is full of 
conflicting and inconsistent data, but some 
general principles may be discerned, and 
more advanced investigative technics will 
eventually elucidate the various disease 
mechanisms. The basis for the classification 
of these thrombocytopenias is a decrease in 
vivo life-span, with normal megakaryocyte 
activity.23 A production deficit may be asso-
ciated, but it is probably secondary to bone-
marrow exhaustion following hyperplasia 
induced by the increased peripheral destruc-
tion. 
The major disease in this category is so-
called idiopathic thrombocytopenic purpura. 
We probably should abandon the first word 
of the name, since many definitely proven 
etiologies have been described, and in fact, 
these various causes may all precipitate the 
same disease. 
Idiopathic thrombocytopenic purpura has 
been differentiated into two clinical forms126 : 
an acute, self-limited thrombocytopenia 
which usually shows recovery within four 
months of onset, and a chronic form exhibit-
ing remissions and frequent exacerbations, 
and showing decreased platelet levels (less 
than 50 per cent of normal) even during 
periods of clinical remission. In the differ-
ential diagnosis of these two forms of idio-
pathic thrombocytopenic purpura, the fol-
lowing points should be considered: the 
chronic form is more frequent in females 
and in older age groups, almost always pre-
sents with a past history of untoward bleed-
ing, rarely shows any accompanying lym-
phocytosis or eosinophilia, more frequently 
gives a positive family history of bruising or 
thrombocytopenia, and about two-thirds of 
the patients will respond to splenectomy, the 
major form of therapy. 
The cause of the platelet depression 1s 
generally considered to be immunological m 
origin, but the nature of the antibody is in 
dispute, and, in fact, several antibodies may 
be involved. Tullis127•128 has shown that the 
platelet antibodies of patients with idio-
pathic thrombocytopenic purpura are true 
antibodies, found in the gamma-globulin 
fraction of idiopathic thrombocytopenic pur-
pura plasma; these antibodies are selectively 
removed by absorption with normal human 
platelets, and their electrophoretic pattern 
shows them to lie in the region of electrical 
neutrality. A platelet agglutinin is found in 
the beta2-globulin fraction. 129 In the pres-
ence of complement, platelets that have 
been agglutinated by antiserums undergo 
lysis.t"° Certain unrelated antigen-antibody 
complexes may be adsorbed on platelets, 
leading to their agglutination, and their lysis 
in capillaries, with release of serotonin and 
histamineY0 The direct antiglobulin con-
sumption test gives similar results and per-
mits the demonstration of intracellular anti-
bodiesY1•132 The Coombs test may also be 
positive on platelets from patients with idio-
pathic thrombocytopenic purpura129•133 and 
may be positive with platelets from patients 
with hemolytic anemia but without throm-
bocytopenia.134 It is of interest to note, in 
this connection, that in patients with active 
red-blood-cell hemolysis due to deficient 
red-cell glucose-6-phosphate dehydrogenase, 
their platelets also show a deficit of the 
enzyme, but no thrombocytopenia.135 
Plasma from patients with idiopathic 
thrombocytopenic purpura reduces the plate-
let count of normal recipients.129•136•137 This 
property may remain after splenectomy, but 
a normal platelet count may also be main-
tained.136 
The problem of false-positive platelet anti-
body tests occurs but infrequently. Those 
found in patients with cirrhosis or conges-
tive splenomegaly may actually be due to an 
unmasking of nonantibody cytotoxicity by 
the associated hypoalbuminemia.128 Other 
false positives have been eliminated by the 
removal of calcium and barium sulfate-
adsorbable serum factors. 138 A very recent 
study finds no evidence for any platelet anti-
bodies in idiopathic thrombocytopenic pur-
pura/39 and suggests that the platelets con-
tain a separate protein moiety which acts as 
an antigenic stimulus. An incomplete anti-
body has been shown in 50 per cent of plate-
let antibody serums.140 
The frequency of finding platelet anti-
bodies varies.127•131"133·138 They can be dem-
onstrated in 0 to 4 per cent of normal sub-
jects, in 21 to 70 per cent of patients with 
idiopathic thrombocytopenic purpura, in 2 
to 23 per cent of cases with secondary throm-
bocytopenic purpura, in 66 per cent of 
hypersplenic syndromes, and in 99 per cent 
of patients with systemic lupus erythemato-
sus. 
The bone marrow of patients with idio-
pathic thrombocytopenic purpura shows an 
increased number of megakaryocytes, pre-
dominantly young forms, with decreased 
granularity and platelet production; degen-
erative changes are seen in nucleus and cyto-
plasm.123 Platelets that are formed are fre-
quently large and bizarre, and have been 
shown to bind less serotonin than nor-
mally.123•141 This evidence, and other data 
discussed above, have suggested that idio-
pathic thrombocytopenic purpura attacks 
both the platelet and its parent cel].l23•129 
The role of the spleen in idiopathic throm-
bocytopenic purpura is still open to question, 
though it probably does remove sensitized 
platelets, and perhaps produces a platelet 
agglutinin.137 However, no differences were 
found in the platelet counts of splenic-artery 
and splenic-vein blood in idiopathic throm-
bocytopenic purpura or any other condition 
investigated.142 It has been suggested that 
the spleen regulates the maturation and re-
lease of platelets, possibly under adrenal 
cortical influence, and explaining the efficacy 
of ACTH in some cases of idiopathic throm-
bocytopenic purpura.143 Further evidence for 
this role of the spleen is the finding that after 
the injection of an aliquot of chromium51-
labeled platelets, they do not appear in the 
circulation for several hours, indicating some 
sort of temporary sequestration. 23 A few 
cases of idiopathic thrombocytopenic pur-
pura subjected to splenectomy have shown 
abnormal histiocytes, filled with phospho-
lipids (largely sphingomyelin) .144•145 This 
phenomenon may be due to reticuloendo-
thelial phagocytosis of platelets, but appar-
ently occurs so very rarely as to leave its 
etiology in considerable doubt. 
Neonatal thrombocytopenic purpura137 
may be found in the infants of mothers with 
idiopathic thrombocytopenic purpura, as a 
result of the transplacental transfer of ma-
ternal platelet agglutinins. More rarely, it 
may be due to the development of isoagglu-
tinins arising from fetal and maternal plate-
let incompatibility. Platelet antibody tests are 
positive in about two-thirds of these mothers 
and babies, but not always in both at the 
same time.127 
Idiopathic thrombocytopenic purpura has 
been found to be the forerunner of systemic 
lupus erythematosus in growing num-
bers.146'147 In one series of 51 splenectomized 
patients with idiopathic thrombocytopenic 
purpura at least 31.4 per cent developed 
other manifestations of systemic lupus ery-
thematosus, and 15.7 per cent developed the 
full-blown syndrome. These patients are pre-
ponderantly females. It is, therefore, of the 
utmost importance to consider virtually every 
case of idiopathic thrombocytopenic purpura 
as a potential case of systemic lupus ery-
thematosus, and to maintain long-term fol-
low-up studies on all patients with idiopathic 
thrombocytopenic purpura. Though it has 
been thought in the past that other rheuma-
toid diseases occasionally exhibited thrombo-
cytopenia, it is most likely that such cases 
were actually systemic lupus erythematosus 
which had not been fully diagnosed. The 
finding of platelet antibodies in 99 per cent 
of patients with systemic lupus erythema-
tosus132 may reinforce the autoantibody con-
cept of the basis for idiopathic thrombocyto-
penic purpura. It should be mentioned here 
that no platelet abnormality has been re-
ported in patients with the discoid form of 
lupus erythematosus. 
Clinically, idiopathic thrombocytopenic 
purpura and most other forms of thrombo-
cytopenia, as well as the qualitative defects 
of platelets, present with petechiae and ecchy-
moses. Hematomas, cerebral and gastrointes-
tinal hemorrhage, and hemarthroses, are 
other frequent findings. Screening of the 
patient's coagulation status reveals increased 
bleeding time and capillary fragility, de-
creased prothrombin consumption and clot 
retraction, and normal clotting time. Pro-
thrombin consumption and clot retraction 
are directly proportional to the platelet 
count.148 Recent work149 indicates that there 
is little correlation between the platelet count 
and the occurrence of purpura and hemor-
rhage. Instead, an obscure link between 
hemorrhagic phenomena and platelet throm-
boplastic factor, probably identical or similar 
to Platelet Factor 3, is postulated, with pur-
puric manifestations first occurring at platelet 
thromboplastic factor levels of 25 to 55 per 
cent of normal, and hemorrhage with less 
than 25 per cent of normal platelet thrombo-
plastic factor levels. This work requires more 
extensive and carefully controlled confirma-
tion. 
It may turn out to be of interest in the 
study of the pathogenesis of idiopathic throm-
bocytopenic purpura, and of aplastic anemia 
with thrombocytopenia, that the leukocyte 
alkaline phosphatase levels are moderately 
low in these diseases.150 Supranormal levels 
of this enzyme are obtained with ACTH 
and steroid therapy. 
Besides the "idiopathic" form, there are 
several forms of thrombocytopenic purpura 
of known etiology. Many drugs induce im-
munological thrombocytopenia. The mecha-
nisms were first elucidated for Sedormid 
(allyl-isopropyl-acetyl-carbamide) .151•152 Se-
dormid combines with the platelets of "sensi-
tive" patients to form an antigen complex; 
this antigen and its antibody induce platelet 
lysis in the presence of complement. A simi-
lar mechanism occurs with capillary endo-
thelium, so that the resulting hemorrhagic 
tendency is due not to the thrombocytopenia 
alone. Those patients who are sensitive to 
Sedormid are also sensitive to other chemical-
ly related compounds. 
Similar evidence has been presented for 
thrombocytopenia due to quinidine hypersen-
sitivity.153 In this case, the antibodies attach 
to a platelet-quinidine complex, but com-
plement is fixed between two antibody mole-
cules only when both antibodies have exactly 
two (not one or three) quinidine molecules 
attached. This high degree of specificity 
led to the suggestion that the adsorbed anti-
body so changed the platelet membrane as 
to cause its removal from the circulation, 
by phagocytosis or other splenic action; this 
mechanism may be very like that which oc-
curs in idiopathic thrombocytopenic purpura. 
Quinidine-induced thrombocytopenia154 is an 
acute self-limiting disease with a good prog-
nosis if the drug is stopped early in its 
course. The diagnosis may be suggested by 
the clinical appearance of hemorrhagic bul-
lae on the oral mucosa. 
Other drugs known to produce what are 
probably similar phenomena include certain 
barbiturates, pyrazolones, sulfonamides and 
arsenobenzols; quinine; chlorprophenpyrida-
mine; digitoxin; PAS; and DDT. An even 
longer list has been incriminated at one 
time or another.102 One last common drug 
that is known to induce thrombocytopenia, 
but rather due to some undetermined type 
of megakaryocyte suppression, is prednisone 
in high dosage, 155 used for maintenance of 
patients with idiopathic thrombocytopenic 
purpura. In preliminary clinical trials, intra-
venous fat emulsions have produced several 
thrombocytopenic conditions156•157 ; these are 
thought to be due to overloading of the anti-
body mechanism of the reticuloendothelial 
system with fat, with subsequent activation 
of a pathologic virus-platelet antigen com-
plex. 
A large group of infectious diseases has 
been implicated in thrombocytopenic pur-
pura. Remission of the disease usually is 
accompanied by a return to normal platelet 
levels, unless hemorrhage intervenes. It may 
be seen in tuberculosis, 158 usually when there 
is marrow involvement by the invading or-
ganism. A fulminating purpura may occur 
after scarlet fever, and mild thrombocyto-
penia may occur with various streptococcal 
infections.159 The anticoagulant effect of cer-
tain bacterial polysaccharides appears to be 
enhanced in the presence of platelet-deficient 
plasma, as in leukemia.160 
Viruses have been responsible for some 
instances of thrombocytopenic purpura and 
purpura fulminans. Among those viruses so 
far incriminated are varicella/61 •162 mumps,'"" 
rubeola, 164 and rubella.165·166 In uncompli-
cated rubella, platelet counts were found 
to be low in most cases, and capillary fragil-
ity high, at the onset of the disease; these 
findings reversed during convalescence.',;" In 
most cases, a hypersensitive mechanism has 
been postulated. Influenza virus167 is thought 
to be an antigenic link between platelets 
and red blood cells, inducing their mixed 
agglutination. Human bone-marrow pan-
hypoplasia has been produced experimentally 
with Venezuelan equine encephalitis virus, 
though the responsible mechanisms were not 
discussed. 168 Thrombocytopenia has been 
noted in one disease of possible viral origin, 
infectious mononucleosis, though it was 
ascribed to hypersplenism.169•170 Several cases 
of a syndrome of hemolysis, thrombocyto-
penia and renal disease have been re-
ported171•172; an allergic response to a viral 
infection, possibly of the lower intestinal 
tract, was postulated for some of these pa-
tients. It has been speculated165 that if an 
immunological activity is responsible for these 
cases, with a virus-platelet complex acting 
as an antigen, may not many cases of "idio-
pathic" thrombocytopenic purpura be due, 
in reality, to a virus, especially following un-
recognized infections? Though the long 
course of most thrombocytopenias argues 
against this hypothesis, it certainly warrants 
further careful, prospective investigation. 
Thus, the nature of the platelet antibodies 
is still a mystery. It is not known whether 
they are different for each precipitating case, 
or whether they are homogeneous. The ap-
pearance of thrombocytopenia with viral dis-
eases may not be due to any hypersensitive 
mechanism, but may represent some extreme 
form of the disease. In this regard, it may 
be remembered that in most of these cases, 
at least in those in which a virus is recover-
able at all, the infecting agent cannot be 
isolated by the time clinical manifestations 
appear, presumably because by that time 
t!le body's defenses have produced enough 
antibody to neutralize the invading virus, 
and yet this is the time when the thrombo-
cytopenia appears. Does the virus enter the 
platelet and/or megakaryocytes and produce 
its effects intracellularly, and thus be outside 
the range of antibody action? 
Finally, t1~ere is a question as to the origin 
of th~ p!atelc:t antibody. Current thought is 
that it is autoir:1rnune in nature, but it cannot 
be proven by any technics now available and 
only Hashimoto's disease of the thyroid has 
so far fitted all criteria for autoimmune dis-
ease. The evidence so far presented in a few 
well-studied cases argues in favor of an iso-
antibody in response to a complex of platelet 
and exogenous agent, perhaps unidentifiable, 
such as a virus or drug. Antibodies similar to 
those of the blood groups cannot be ruled 
out, and neither can cross-reactivity between 
platelets and the foreign material. We can 
only hope that there will be less precipitous 
opinionating and more recourse to sophisti-
cated technology in the answering of these 
questions. It should be remembered that cur-
rently available laboratory methods cannot 
elucidate any responsible mechanisms. 
Aldrich's syndrome is a rare fatal disease 
manifested as thrombocytopenia, eczema and 
infection in infants. 173 •174 Platelet production 
is normal, as is the immune response. The 
basic condition seems to be a genetically 
determined liability to infection, with a sec-
ondary thrombocytopenia. 
The remaining forms of thrombocytopenia 
due to increased peripheral removal are more 
mechanical in their pathogenesis. One rare 
entity is thrombocytopenia due to sequestra-
tion of the platelets within a giant hemangi-
oma in infants. 175 The resulting purpura IS 
reversed with x-irradiation to the tumor. 
Thrombotic thrombocytopenic purpura is 
a bizarre syndrome which includes hemolytic 
anemia and neurological symptoms_l76 -179 
Pathological studies show endothelial prolif-
eration and platelet thrombi in terminal ar-
terioles and capillaries. The disease is rapidly 
progressive and fatal and is usually diagnosed 
only at autopsy. It appears to be the result of 
a hypersensitive state of the red blood cells, 
platelets and endothelium, though no platelet 
agglutinins or red-blood-cell hemolysins have 
been demonstrated; a shortened platelet life-
span has been shown. More recently, it has 
been suggested that thrombotic thrombocyto-
penic purpura is pathogenetically similar to 
eclampsia, and that the thrombi are com-
posed not of platelets but of fibrin.180 
The role of the platelets in shock has been 
explored to some extent. In experimental 
hemorrhagic shock in the rabbit, 181 three 
phases are noted: an initial hypercoagulable 
stage, with increased platelet counts and 
thromboplastin generation and a rapid de-
crease in fibrinogen; this is followed by ab-
normally low platelet levels, fibrinogen con-
centration and plasma coagulation factors; 
the final stage is a return to normal levels 
of these parameters if the bleeding is stopped. 
Widespread intravascular clotting was seen 
histologically, possibly around foci of platelet 
microthrombi. Studies on anaphylactic and 
peptone shock'8" in the rabbit reveal that 
the degree of thrombocytopenia is a constant 
indication of antigen sensitization and severity 
of shock. At the same time, there is a correla-
tion between the disintegration of white 
blood cells and platelets and the liberation 
of histamine. The intracellular reaction be-
tween antigen and antibody apparently re-
sults in the activation of a proteolytic en-
zyme, probably trypsin, which releases hista-
mine bound to intracellular protein. The 
disintegrated platelets appear to clump and, 
with the added influence of histamine, ob-
:;truct the small blood vessels. However, the 
hemorrhage seen in thrombocytopenic shock 
is not due to the fall in circulating platelets, 
but to products of their disintegration. These 
mechanisms may not operate in man, whose 
platelets contain less histamine than those 
of rabbits, but they nevertheless provide a 
model for future investigation. 
Surgery and some of its special technics 
have measurable effects on human platelet 
levels. A 10 per cent increase in platelet 
count is found immediately postoperatively 
in nontransfused normothermic patients.183 
The platelet count returns to preoperative 
levels in about three days. Marked thrombo-
cytopenia is usually seen in operations under 
hypothermic conditions at 25° C. or below, 
associated with increased clotting time and 
decreased prothrombin consumption.184 Ex-
tracorporeal circulation technics destroy large 
amounts of both donor and recipient plate-
lets.185-187 The abnormal bleeding observed 
after some of these operations does not seem 
to be due to the thrombocytopenia so much 
as to the hypercoagulability and subsequent 
intravascular clotting due to platelet disrup-
tion. As a result, plasma coagulation factors 
are depleted and increased fibrinolysis oc-
curs, leading to a hemorrhagic diathesis. 
Platelet Factor 4 deficiency may be involved 
as well. 
Thrombocytopenia and bleeding are fre-
quently induced by exchange transfusion or 
the massive transfusion of banked blood 
stored for more than one day.188-190 This ef-
fect is enhanced in patients with pre-exist-
ing coagulation abnormalities, as in liver 
disease and hypersplenic syndromes, and is 
largely due to the inability of stored blood 
platelets to circulate. It is also possible that 
platelets are consumed during storage by 
slowly progressive thromboplastic activity 
which is not completely prevented by stan-
dard anticoagulating technics. All patients 
in whom massive transfusion is deemed prob-
able, especially those with hepatic damage, 
should have preoperative studies of their 
platelet levels and prothrombin-complex fac-
tors performed, and fresh blood should be 
made available. Transfusion reactions have 
also been associated with thrombocyto-
penia/91 secondary to intravascular clotting 
and release of platelet thromboplastin. 
THROMBOCYTOSES 
Increased numbers of platelets are also 
associated with bleeding dyscrasias. 
Hemorrhagic thrombocythemia192-194 is a 
rare and unusual myeloproliferative disorder 
of the platelets, in which the severity of the 
bleeding manifestations is roughly propor-
tional to the platelet count. The platelets 
are probably functionally norn1al, since they 
will correct the bleeding of a thrombocyto-
penic recipient. The platelets of patients 
afflicted with hemorrhagic thrombocythemia 
have been found to bind less serotonin than 
those of normal subjects, but this may be 
because the number of platelets in the body 
exceeds the available serotonin stores. In 
some patients, the spleen has been found to 
be absent or atrophic, but it has been en-
larged in others. The hemorrhagic episodes 
have been ascribed to an anticoagulant effect 
of the excess platelets, inhibiting the throm-
boplastin phase of coagulation. 
Polycythemia vera114•195'197 is probably a 
divergent form of myeloproliferative disorder. 
Platelets from polycythemic blood show a 
shortened life-span when infused in thrombo-
cytopenic recipients, but any hemorrhagic 
manifestations in the recipients remain im-
proved for several hours after the transfusion. 
It is now thought that the bleeding tendency 
seen in some polycythemic patients is most 
likely due to a qualitative defect of platelets, 
Platelet Factor 3 deficiency. Exaggerated 
structural metamorphosis is also seen. Bone-
marrow depressants such as radioactive P32 
and urethane seem to be of some value in 
the control of the disease, though periodic 
phlebotomy is the traditional regimen. 
An interesting facet of the thrombocytotic 
syndromes is the appearance of hyperka-
lemia, 198 due to the release of potassium 
from the excess number of platelets. There 
is no increase in platelet potassium concen-
tration. As yet, no signs or symptoms of 
hyperkalemia have been reported in these 
patients. 
QuALITATIVE DEFECTS OF PLATELETS 
These diseases have long been regarded as 
a group of esoteric and unexplained condi-
tions, whether primary platelet dyscrasias 
or secondary to other diseases. In the last 
few years the pathophysiology has been de-
termined for some of them, and important 
inroads have been made in others. 
Thrombocytopathy, a purpuric condition 
characterized by increased bleeding time, 
normal clot retraction and platelet count, 
and defective prothrombin consumption and 
platelet thromboplastin generation test, is 
thought to be due to an inability of the plate-
lets to release Platelet Factor 3 upon activa-
tion of the coagulation mechanism.U4·199·201 
There is no intrinsic deficit of Platelet Factor 
3, since incubation of the patient's platelets 
in distilled water, or their subjection to 
sonic oscillation, permits their normal per-
formance in the thromboplastin generation 
test, but the platelets show an increased 
osmotic resistance. Defective aggregation but 
excess structural metamorphosis are seen, and 
the chromomere, which contains Platelet 
Factor 3, is not released easily. There appears 
to be no defect in capillary structure. Aniso-
cytosis of the platelets has been described, 
and as~ribed to an abnormal cell-wall lipo-
protein. The disease produces a mild to 
moderate hemorrhagic diathesis, and is 
thought to be the result of non-sex-linked 
simple dominant genetic transmission. It has 
also been reported in association with AHF 
deficiency, as thrombocytopathia hemophili-
ca. 201 
Thrombocytoasthenia is a disease charac-
terized by increased bleeding time, normal 
platelet count and Platelet Factor 3, and 
decreased clot retraction.199·201 Morpholog-
ically, the platelets show defective pseudopod 
formation and adhesiveness, with lack of 
hyalomere spreading. It is not known whether 
the disease arises spontaneously, or if it is 
due to a simple recessive genetic factor. 
In association with AHF or PTC deficiency, 
this condition is known as thrombocytoas-
thenia hemophilica, but it is further dis-
tinguished from the more frequent disease 
by normal clot retraction. 201 
A combination of these two diseases has 
been described as thrombocytoasthenia throm-
bocytopathia, manifested by increased bleed-
ing time, decreased clot retraction and 
Platelet Factor 3 release, and normal platelet 
count. 201 Morphologically, defective aggrega-
tion, adhesion, pseudopod formation and 
hyalomere spreading of the platelets are 
seen. 
Macroglobulinemia frequently presents with 
a hemorrhagic diathesis. This has been shown 
to be due to the physicochemical activity of 
the abnormal globulin covering the platelet 
and preventing the release of Platelet Factor 
3. 202•203 There is no evidence for any ant: 
platelet immunological activity of the "'-' 
normal globulin; its inhibitory effect appears 
to be directly proportional to its molecular 
size. Dendrites are not formed by the affect('cl 
platelets, presumably due to a restraining 
capacity of their protein covering. Screening 
tests will usually reveal increased bleeding 
time, normal clot retraction, decreased pro-
thrombin and prothrombin consumption, and 
low levels of fibrinogen; circulating antico-
agulants may have to be ruled out. There is 
evidence that dextran may act in much the 
same way in massive doses. 204 
The pathogenesis of bleeding in leukemia 
is not well understood. Current evi-
dence114'149•205'208 fails to demonstrate any 
consistent deficiencies that can cause bleed-
ing. Thrombocytopenia and deficient plasma 
Factor V levels are most frequently found, 
but they do not correlate with the hemor-
rhagic tendency. Platelet thromboplastic 
function is frequently decreased, as is serum 
serotonin (i.e., either platelet serotonin or 
platelet release of serotonin) . Clinical bleed-
ing rarely occurs at platelet levels over 50,000 
per cubic millimeter, but it may, and bleed-
ing does not always occur at even lower 
platelet counts. Structural metamorphosis 
may not occur, and platelets may be swollen 
and without dendrites. Thus it seems that 
the overall functional hemostatic activity of 
the platelet is involved in leukemic hemor-
rhage, and probably includes vascular fac-
tors as well. 
In other malignancies, thrombocytopenia 
is occasionally seen secondary to bone-mar-
row invasion by the tumor cell. However, 
functional defects in the platelet may also 
be detected on rare occasions. 
Uremia is occasionally accompanied by a 
bleeding abnormality. The hemorrhagic tend-
ency has been ascribed and denied to many 
mechanisms,64 •209- 215 and probably no one in-
dividual mechanism is responsible in all cases. 
Roughly half of all bleeding uremic patients 
exhibit mild to moderate thrombocytopenia. 
Some of the rest show normal platelet counts 
but definite thrombocytopathies have been 
demonstrated in them, including deficiencies 
of Platelet Factors 3 and 4. Deficiencies in 
some of the plasma coagulation factors have 
been found in a few patients. Platelet sero-
tonin is frequently low. Capillary fragility is 
occasionally observed. Clotting and bleeding 
times may be prolonged, but clot retraction 
is usually normal. No morphologic abnormali-
ties have been described in the platelets, and 
thrombopoiesis appears to be normal. Plate-
let phosphatides are normal. In these studies 
no correlation between blood urea nitrogen 
or nonprotein nitrogen and bleeding was 
found, and urea was found not to be the 
major factor. There was some degree of 
correlation between bleeding and duration 
of anuria in acute renal failure, but not in 
long-standing chronic disease. In the face of 
this evidence, we can only accept a postu-
late of multiple qualitative and quantitative 
defects of unknown origin at this time. 
Liver disease is frequently accompanied by 
platelet defects. 91 • 209 -~ 16 Mild thrombocyto-
penia has been reported, but a defect in 
platelet thromboplastic act1v1ty (Platelet 
Factor 3?) has been found most often, usual-
ly associated with decreased plasma coagula-
tion factors. Platelet Factor 4 has also been 
found decreased. 
THERAPY OF PLATELET DISORDERS 
The management of the diseases discussed 
in the previous section of this review presents 
some of the most challenging problems in 
modern medicine. It must be emphasized at 
the beginning that there is no standardized 
regimen for any of these cases, but most re-
quire subtle manipulation of existing tech-
nics. In addition, we are gradually building 
up an armamentarium of new agents that 
show promise for the near future. 
Not all of the platelet diseases are amena-
ble to treatment by their nature. The major 
treatable diseases, which numerically .outrank 
all the others, are the thrombocytopenias, 
and these are the main topic of the remainder 
of this review. The primary qualitative de-
fects are largely untreatable, but are also 
frequently mild and not life-threatening. In 
such patients, replacement and supportive 
therapy are usually beneficial in hemorrhagic 
crises. Treatment of the underlying cause of 
secondary qualitative and quantitative defects 
will usually correct the hemorrhagic tend-
encies. The thrombocytoses show remission 
following phlebotomy. 
The generally accepted critical platelet 
level is 50,000 per cubic millimeter; bleeding 
is more likely to occur at levels of less than 
10,000 per cubic millimeter, and does not 
occur with more than 100,000 platelets per 
cubic millimeter in the absence of qualitative 
platelet or other coagulation factor defects 
(though a few patients undergoing major 
surgery will bleed with 150,000 platelets per 
cubic millimeter, largely due to associated 
plasma protein defects) .217 Clinically, we 
should like to maintain levels of at least 
about 100,000 platelets per cubic millimeter. 
Bone-marrow transfusion has become the 
treatment of choice for irradiation in jury 
syndromes106•218 in the absence of other dis-
ease, and isologous grafts appear to perform 
the entire hematopoietic function for a month 
or so until the patient's own marrow re-
covers. Autologous, homologous and isolo-
gous bone-marrow transfusions have been used 
with varying success in producing temporary 
remission of leukemia following whole-body 
x-irradiation. 219-222 The technic has also been 
used successfully in aplastic anemia223 and 
secondary thrombocytopenia of unknown ori-
gin.224 
Whole-blood transfusion is useful in the 
management of mild qualitative and quanti-
tative deficiencies of platelets. As noted earli-
er, it must be fresh in order to supply appro-
priate amounts of platelets. Five per cent of 
donor platelets are lost by collection alone 
into acid-citrate-dextrose solution in glass 
bottles or plastic bags, followed by a 2 to 3 
per cent loss daily during storage for twenty-
one days. 225 No morphological changes were 
noted. However, despite this slow loss of the 
platelets themselves, the remaining platelets 
show a survival time inversely proportional 
to the length of storage of the blood, 226•227 
as determined by their ability to circulate 
in the recipient's bloodstream. 
In an effort to study the platelet defects 
which develop during routine blood banking 
storage of whole blood anticoagulated with 
acid-citrate-dextrose and stored in plastic 
bags, with the idea of salvaging the platelets 
remaining after twenty-one days of storage 
at 4° C., the author has measured the major 
platelet factors and some metabolic aspects 
of fresh and stored platelets.43 Platelet Fac-
tors 1 and 2 were severely diminished after 
twenty-one days; Platelet Factors 3 and 4 
were normal; clot retraction decreased 
gradually until its complete disappearance 
in fourteen to twenty-one days; aerobic 
and anaerobic metabolism by the platelets 
was not significantly reduced at the end of 
the storage period. These results, along with 
those of others, 228 indicate that from all 
parameters that can be studied conveniently, 
platelets in blood stored for more than one 
day should be effective in the control of 
hemostasis, or at least some aspects of it. 
Platelet transfusions have been the subject 
of much study in recent years. They are de-
sirable largely in the hope of avoiding over-
transfusion with whole blood in patients 
whose major defect is primary or secondary 
thrombocytopenia. 229 Fresh platelets, collected 
in acid-citrate-dextrose, separated by differ-
ential centrifugation from blood of com-
patible blood groups, and resuspended in the 
parent plasma, are given for many thrombo-
cytopenic emergencies. However, this method 
is cumbersome for most blood banks, and a 
method of preserving separated platelets 
alone is in great demand. It must be remem-
bered that even fresh platelet transfusions are 
not always useful, as in idiopathic thrombo-
cytopenic purpura, in which the infused 
platelets are destroyed soon after infusion. 
In these patients, platelet transfusion is valu-
able immediately after splenectomy. 230 Re-
fractoriness may develop to multiple platelet 
transfusions, with decreased platelet survival 
and perhaps development of antiplatelet sub-
stances in some cases. 230•231 In one series, no 
platelet antibodies could be demonstrated 
after multiple hemostatically effective fresh 
platelet transfusions. 232 
Platelet preparations are usually evaluated 
by their ability to depress the appearance 
of red blood cells in the lymph of the cannu-
lated thoracic duct of x-irradiated dogs, 233 
by measurement of their life-span/34•235 or by 
various in vitro technics for studying indi-
vidual clotting factors. Of those platelet 
preparations which have been studied, the 
following have showed some indication of 
usefulness, but none has been used exten-
sively or is likely to be in the near future: 
collected in plastic bags and EDT A/34•236 
frozen in parent plasma, 237 and frozen in 
EDT A and/ or glycerol. 235•238 Lyophilized 
(freeze-dried) platelet material/39-241 and 
platelets preserved in gelatin at 4° C., 242 
have shown most promise clinically. A 
cephalin complex has been reported to pro-
duce favorable changes in patients with idio-
pathic thrombocytopenic purpura.243 Ex-
change transfusion may be of value in con-
genital thrombocytopenic purpura with 
platelet antibodies, manifested in infants.244 
The management of idiopathic thrombo-
cytopenic purpura is only occasionally diffi-
cult. Each patient requires individually tai-
lored therapy, but if properly thought out 
and executed permanent remissions are fre-
quently obtained. 
Platelet transfusions, including whole-blood 
transfusions, may be useful in acute hemor-
rhagic crises of idiopathic thrombocytopenic 
purpura, and in preparation for surgery, but 
they are wasted in long-term treatment, for 
the reasons discussed above. They are most 
valuable in the amegakaryocytic thrombo-
cytopenias. 240 
Splenectomy alone produces complete re-
mission in 60 to 90 per cent of cases of 
idiopathic thrombocytopenic purpura in most 
large series/47 •246 - 248 and is more likely to 
be efficacious if the patient has previously 
showed some response to steroids, 248 though 
in these same series steroid therapy alone 
produced few complete remrsswns. The 
steroids most likely to be clinically use-
ful are cortisone and prednisone, along with 
ACTH. 249 • 252 Care must be taken with pred-
nisone, since in high doses it shows a throm-
bocytopenic effect. 155 The clinical effects of 
these drugs are usually due, however, to 
improvement of vascular fragility, and not to 
any direct effect on platelets. Steroids are 
definitely indicated in preparation for sple-
nectomy, and may be useful in moderate 
nonsurgical cases. It should be remembered 
that children and adolescents are likely to 
undergo spontaneous remission, and should 
be followed carefully for six to twelve months 
before drastic treatment is instituted. 24 G 
Aplastic anemia has recently been 
treated successfully with testosterone in some 
cases. 203 •254 Even without complete remis-
sions, the hormone permits the maintenance 
of satisfactory platelet levels. Previously, the 
only useful therapy has been repeated blood 
transfusions. 
SUMMARY 
The recent literature of the normal and 
abnormal structure and function of the plate-
let has been reviewed, with emphasis on the 
pathophysiology of the platelet disorders. 
There are still many questions to be an-
swered. One of the most pressing is the 
nature of the antibody reaction in idiopathic 
thrombocytopenic purpura; though the evi-
dence suggests that an isoantibody to a plate-
let-foreign substance complex is responsible, 
other forms must be ruled out. The role of 
serotonin in platelet physiology remains to 
be elucidated, and practical methods of plate-
let preservation and transfusion remam un-
discovered at this time. 
I wish to express my gratitude to Drs. Edgar 
E. Baker and Matthew A. Derow, of the Depart-
ment of Microbiology, Boston University School 
of Medicine, for their help in my understanding 
of the problems of platelet antibodies, and to 
Dr. Charles P. Emerson, of the Department of 
Medicine, Massachusetts Memorial Hospitals, for 
his guidance in the preparation of this paper. 
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